Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
64.78 USD | -0.22% | -0.82% | -20.02% |
07/05 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
02/05 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.02% | 80.95B | |
+32.94% | 698B | |
+26.51% | 568B | |
-4.63% | 358B | |
+19.38% | 328B | |
+3.47% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.66% | 165B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences Says Study Results Back Use of Veklury for People With COVID-19